Skip to main content
. 2021 Feb 25;13(5):957. doi: 10.3390/cancers13050957

Figure 3.

Figure 3

B. bre JCM92 boosts oxaliplatin efficacy by enhancing anti-tumor immunity. (A,B) Immune cell profiling of tumor tissue in mice treated with oxaliplatin in combination with B. bre JCM92 (A) or B. bre Bb03 (B) using flow cytometry analysis. Data are expressed as the means ± SEM. p-values were determined by one-way ANOVA using Tukey’s post-test. (C) Expression of intratumoral cytokines in mice treated with oxaliplatin combined with B. bre JCM92 or B. bre Bb03 were measured using qPCR. Data are expressed as the means ± SEM. p-values were determined by one-way ANOVA using Tukey’s post-test within oxaliplatin treated groups. For all graphs, * p < 0.05, ** p < 0.01, *** p < 0.001, and ns, not significant.